Study of PCC1 for Skin Rejuvenation

NCT06641869 | Completed

• 1 other identifier: EXRX023
• Study Type: interventional
• Target: 74
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial will assess the efficacy of PCC1 for skin rejuvenation. The primary objective is to determine whether these interventions enhance skin barrier function, reduce wrinkles, and improve skin texture and radiance over a 12-week period. The study will involve healthy participants applying the treatments and undergoing assessments at baseline, 6 weeks, and 12 weeks. Secondary objectives include evaluating the safety and tolerability of PCC1, with any adverse effects closely monitored during the trial.

Conditions

Skin Rejuvenation

Outcome Measures

Primary Outcomes (3)

• Skin Barrier Function

  Measured via Trans-Epidermal Water Loss (TEWL) using a VapoMeter at baseline, week 6, and week 12.

  at baseline, week 6, and week 12.

• Wrinkle Reduction

  Quantified using Antera 3D imaging analysis for wrinkle indentation.

  at baseline, week 6, and week 12.

• Skin Texture and Radiance

  Evaluated via VISIA-CR imaging and expert clinical grading

  at baseline, week 6, and week 12.

Secondary Outcomes (2)

• Self-Perceived Skin Improvements

  12 weeks

• Safety and Tolerability

  12 weeks

Study Arms (3)

PCC1 Group

EXPERIMENTAL

Dosage Form: Oral dietary supplement. Dosage: 2.5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.

Dietary Supplement: procyanidin C1

Placebo

PLACEBO COMPARATOR

Dosage Form: Oral placebo supplement. Dosage: Administered once daily. Duration: 12 weeks.

Dietary Supplement: Placebo

PCC1 Complex

EXPERIMENTAL

Dosage: 5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.

Dietary Supplement: PCC1 complex

Interventions

procyanidin C1 DIETARY_SUPPLEMENT

Proprietarily extracted procyanidin C1

PCC1 Group

Placebo DIETARY_SUPPLEMENT

Placebo

Placebo

PCC1 complex DIETARY_SUPPLEMENT

5 mg of procyanidin C1. Frequency: Administered once daily. Duration: 12 weeks.

PCC1 Complex

Eligibility Criteria

• Age: 45 Years - 65 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Women aged 45-65
• any skin type according to the Glogau scale
• No significant underlying health conditions affecting skin.
• Willingness to comply with the study protocol.
• Capacity to personally give informed consent (consent via legally authorized representative will not be accepted) and who are willing to comply with all study-related procedures and assessments;

You may not qualify if:

• Presence of any dermatological conditions or use of retinoids or similar compounds within 6 months of the study.
• patients with active skin diseases (e.g. atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis)
• patients using other anti-aging treatments within 1 month

Sponsors & Collaborators

• Express Rx, Inc: lead

Study Sites (1)

University of Geneva

Geneva, Switzerland

Location

MeSH Terms

Interventions

procyanidin trimer C1

Study Officials

• Emilia Loewe

  Express Rx, Inc

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 10, 2024
• First Posted: October 15, 2024
• Study Start: October 10, 2022
• Primary Completion: February 23, 2024
• Study Completion: August 10, 2024
• Last Updated: August 11, 2025

Record last verified: 2025-08

Locations

CH (1)